Should You Buy Eli Lilly and Company Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Eli Lilly and Company (LLY) ranks in the top tier of our coverage universe with a Quality of Company score of 9.4/10. Trading at a market price of $1,136.11, this high-quality profile requires careful comparison against our 13 intrinsic value models.
The short answer: 1 of 9 CirclFi valuation models project upside for Eli Lilly and Company (LLY) at $1136.11 — the model consensus leans bearish, with a Quality Score of 9.4/10 and Value-Trap risk of 0/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Eli Lilly and Company (LLY) in 2026?
What Is the Bull Case vs the Bear Case for Eli Lilly and Company (LLY)?
| Bull case — $1328.04 target (+16.9%) | Bear case — $122.74 target (-89.2%) |
|---|---|
| According to the CirclFi Quality of Company (QOC) framework, Eli Lilly and Company's score of 9.4/10 reflects durable competitive advantages that should sustain earnings power through market cycles. | According to the CirclFi Deep Alpha Valuation Engine, the RCMH-DCF model sees the stock as overvalued with a fair value of $122.74 (-89.2%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, the Regime Cross-Sectional model targets a fair value of $1,328.04 (+16.9%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +106.1% spread between the most bullish and bearish models, signaling elevated analytical uncertainty. |
| Industry tailwind: licensing and M&A optionality could provide meaningful support for Eli Lilly and Company's revenue and margin trajectory in the Drug Manufacturers - General space. | Industry headwind: generic/biosimilar competition represents a meaningful risk for Eli Lilly and Company and its Drug Manufacturers - General peers. |
| The company's $1.01T market capitalization provides liquidity, stability, and the resource base to invest through downturns — structural advantages over smaller peers. |
How Does LLY Compare to Its Drug Manufacturers - General Peers?
Valuation data pages: MRK · NVO · GILD · AZN · NSRX · JNJ · BMY · PFE · MIRA
Which Other Stocks Score Like LLY on Quality?
Closest companies to LLY’s Quality of Company score of 9.4/10, across all industries.
- ABNB — Airbnb, Inc. (QOC 9.5) · analysis
- IESC — IES Holdings, Inc. (QOC 9.4) · analysis
- TBTC — Table Trac, Inc. (QOC 9.5) · analysis
- NOW — ServiceNow, Inc. (QOC 9.4) · analysis
- IDXX — IDEXX Laboratories, Inc. (QOC 9.5) · analysis
- EPAC — Enerpac Tool Group Corp. (QOC 9.4) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
So Is Eli Lilly and Company (LLY) Worth Buying in 2026?
Our valuation engine sends a clear cautionary signal on Eli Lilly and Company at $1,136.11. 8/9 models flag overvaluation, median fair value sits at $386.72 (-66.0%), and the risk-reward profile appears unfavorable. Quality at 9.4/10 is the one bright spot, but premium quality at the wrong price can still destroy returns. This is a stock where patience — or avoidance — may be the optimal strategy.
These are quantitative model outputs, not investment recommendations. Eli Lilly and Company's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About LLY Stock?
Should I buy LLY stock right now?
Based on CirclFi's multi-model analysis, 1 of 9 models see upside for LLY at $1136.11. The models are divided, which means the investment case depends heavily on your assumptions about Eli Lilly and Company's future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Eli Lilly and Company?
Key risks include: wide model disagreement (982% spread), signaling high uncertainty; general market and sector-specific risks affecting Drug Manufacturers - General companies. Always diversify and consult a financial advisor.
How does LLY compare to its competitors?
Among Drug Manufacturers - General peers, LLY holds a Quality Score of 9.4/10. Comparable companies include MRK (QOC 9.6), NVO (QOC 9.3), GILD (QOC 9.7). The relative ranking helps investors identify whether LLY offers better fundamental quality than alternatives in the same sector.
Is LLY a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. LLY's Quality Score of 9.4/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy LLY at?
CirclFi does not provide target buy prices or price alerts. However, our 9 active models produce fair value estimates ranging from $122.74 to $1328.04. At $1136.11, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for LLY.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad